The pharmaceutical industry has always had a complicated relationship with labeling regulations, but a new lawsuit making its way through the Supreme Court may help settle a longstanding liability dispute. The case, Merck v. Albrecht, pits hundreds of Fosamax patients against Merck & Co. over whether the company should be held liable for failing to update the label of its osteoporosis drug.
According to a Reuters’ report, Merck & Co. attempted to change the warning label back in 2008 after it sent data to the Federal Drug Administration that suggested Fosamax may be linked to certain bone fractures. After reviewing the submission, the FDA denied the proposed updates, citing inaccurate wording as a factor. Merck & Co. wanted to add “stress fractures” to the list of possible side effects, but the FDA believed this did not reflect the more serious “atypical femoral fractures” associated to the drug.
The agency launched an in-depth study of Fosamax in 2010 and ordered manufacturers to revise their labels to include “atypical femoral fractures” later that year. Merck & Co. complied with the FDA’s order, but that did not stop over 1,000 separate lawsuits from being filed by former users of Fosamax who had suffered femoral fractures.
The Supreme Court hears the case
The lawsuit was argued in front of the Supreme Court on January 7th, but a formal ruling has not yet been released. An article posted by FiercePharma one day after the hearing suggested court officials may be leaning toward Merck & Co.’s defense, which would uphold the preemption argument often used by the pharmaceutical industry in similar liability cases. Merck & Co. attorneys argued that the FDA’s rejection of its proposed side effects update should bar future claims of negligence and that it should not be held liable under state law since the federal agency’s decision was adhered to.
Attorneys also argued that a ruling against Merck & Co. would force companies operating in the pharmaceutical space to post speculative warnings to avoid potential lawsuits. This would encourage liability-driven labeling practices, rather than evidence-based warnings that are standard practice.
What this means for drug manufacturers moving forward
A ruling in Merck & Co.’s favor would be a huge win for pharmaceutical companies and drug manufacturers, as it would preserve one of the strongest product liability defenses used in court. The argument maintains that companies are preempted by the actions of federal agencies and are obliged to uphold their decisions under federal law. This case demonstrates the complex interplay of industry practices and federal regulations, though drug manufacturers will likely continue to be held responsible for the content of their labels.
Make sure you’re staying up-to-date with changing regulations and protecting your business from liability suits. Start your label revision process by viewing our selection of label printers at Optimedia Labs’ U.S. page or visit our Canadian site.